Full Report

Know the Business

Bottom line. Cooper is a two-engine medical device company: CooperVision (67% of sales) is a genuinely good business — a global soft contact lens oligopolist with 66% gross margins, recurring single-use refills, and a decade of steady share gains from Biofinity, MyDay and MiSight. CooperSurgical (33%) is the drag — a roll-up of ~600 fertility and women's-health SKUs that delivers only half the margin and has just absorbed $343M of acquisition integration pain. The market is probably overestimating the threat of GLP-1s and LASIK to contact lens demand, and underestimating how much of Cooper's reported earnings volatility is amortization of Surgical deal intangibles rather than true economic cost.

How This Business Actually Works

CooperVision sells a consumable that patients replace on a prescription-locked schedule; CooperSurgical sells into a fragmented specialty-procedure market it is trying to consolidate through acquisition.

CVI Revenue FY25 ($M)

$2,744

CVI Op Margin (%)

26.6

The CVI engine is simple and attractive: a patient walks into an optometrist, gets a prescription, and then re-orders the same SKU every 1 day, 2 weeks, or 1 month for years. Cooper competes against only three other serious players globally — J&J Vision, Alcon and Bausch + Lomb. Manufacturing runs through a tight network (Belgium, Costa Rica, Hungary, Puerto Rico, the UK and the US); single-use silicone hydrogel is the fastest-growing modality and where Cooper has a full product lineup (MyDay premium, clariti value). The incremental dollar drops through at ~35-40% operating margin because the factory is already paid for, the SKU is already stocked at the optical chain, and the optometrist's switching cost for the patient is real.

MiSight is the interesting call option. It is the only FDA-, NMPA- and now MHLW-approved (Japan, August 2025) contact lens to slow myopia progression in 8-12 year-olds. Premium pricing, sticky 3-6 year treatment plans, and a standard-of-care narrative in pediatric optometry. Still small but growing fast — management called out "early traction" on MyDay MiSight in Q1 FY26.

The CSI engine is the opposite of elegant. It is 600+ SKUs assembled by acquisition since 1990, sold through OB/GYNs, surgery centers and fertility clinics. Two sub-pieces:

Office/Surgical ($824M, 61% of CSI) — Paragard (the only hormone-free IUD in the US, ~17% IUD share), cord blood/tissue storage, and a long tail of gynecology instruments. This is defended by a regulated drug-device combo (Paragard) plus OB/GYN channel relationships.
Fertility ($525M, 39% of CSI) — IVF consumables, media, micro-tools, donor gametes, cryostorage and genetic testing. End market grows on demographics (rising maternal age, infertility rates, access) but is fragmented and competes with Vitrolife, Fairfax Cryobank and a long tail.

CSI's operating margin collapsed from 9% to 3% in FY25 because of write-offs, severance and amortization from the Cook Medical and obp Surgical acquisitions. On a non-GAAP basis the underlying margin is closer to low-20s — not 3% — but the point stands: CSI is a harder business than CVI and every dollar of incremental revenue there drops through at roughly half the rate.

The Playing Field

Among big-cap device peers, Cooper sits at the cheaper, lower-growth end of the quality spectrum — good margins, middling returns, too much deal amortization suppressing reported ROE.

No Results

What this reveals. Edwards (EW) is the aspirational benchmark for a focused device company: 78% gross margin, 27% operating margin, 50% ROIC because TAVR is a monopoly-economics category. Cooper is not that — soft contact lenses are a healthy oligopoly, not a monopoly, and CSI is a multi-category roll-up. Hologic posts a 67% ROIC but that number is flattered by a small asset base post-impairments; it is not a like-for-like compounder. Alcon is the clearest direct comparator on CVI — similar gross margin, similar ~25% contact lens share, but Alcon carries a surgical-equipment business with lower gross margins. Bausch + Lomb is a post-spin mess with a weak balance sheet; it sets the floor, not the ceiling.

Cooper's reported ROE of 14% looks pedestrian, but the denominator is inflated by acquisition goodwill. On a cash-return basis (FCF / invested capital ex-goodwill), the CVI segment is a high-teens to low-20s business. Reported ROIC of 23% (Joel Greenblatt basis) reflects that once you strip accounting intangibles.

Is This Business Cyclical?

Cyclical at the edges, not at the core. Contact lens wearers do not suddenly stop wearing lenses in a recession — the base is recurring and prescription-anchored. What moves with the cycle is new fittings (discretionary optometrist visits), premium product mix (dailies over monthlies, MiSight over standard lenses), and elective fertility treatment (IVF cycles are $15-20K out-of-pocket in the US). So demand dips 3-8% in a bad year, not 25%.

The 2020 downturn is the cleanest recent test. COVID shut optometrist offices and paused IVF clinics for most of Q2-Q3 FY20. Revenue fell 8% ($2.65B to $2.43B) and operating margin compressed from 20% to 13% — painful but not catastrophic, and fully recovered by FY21. The 2007-2009 credit cycle barely registered on contact lens demand. The real pressure points are FX (roughly half of sales are outside the US) and interest expense — Cooper carried $2.5B gross debt into FY25 at rate-hike era yields, and $100-114M of annual interest absorbs 2-3 points of net margin.

One cycle-ish risk worth flagging: CSI's fertility sub-segment is more discretionary than contact lenses. IVF cycle counts in the US fell ~15% during 2020 and again softened in 2023-24 when consumer savings normalized. Not a vision-style recession but not recession-proof either.

The Metrics That Actually Matter

Five numbers tell you more about Cooper's value creation than the whole 10-K.

No Results

**Why non-GAAP matters here more than usual.** GAAP operating margin was 17% in FY25 but non-GAAP was 25% on the Q1 FY26 print. The $199M of annual intangible amortization is a real economic cost only to the extent those deal assets are impairing — and most of it (Cook Medical, CSI acquisitions) is already capitalized. A focused CVI-only business would report mid-20s GAAP operating margin. Cooper's reported GAAP EPS understates economic earning power by roughly one-third.

The single most important metric to watch quarterly is CVI organic revenue growth. Every other line item follows from it. If CVI organic drops below 4% for two quarters in a row, that is the first real signal that either (a) contact lens wearers are being poached by J&J's 1-DAY Acuvue Oasys Max or Alcon's Precision1, or (b) the broader wearer base is eroding from LASIK/SMILE surgery or GLP-1-induced vision changes — both theses the bears love and neither currently showing up in the data (Q1 FY26 CVI organic: +3%, a tick below trend, FX-dominated geography impact).

What I'd Tell a Young Analyst

Value Cooper as two companies. Do a sum-of-parts: put CVI on 18-22x EV/EBITDA (its peers Alcon and J&J Vision Care trade there), put CSI on 11-14x (roll-ups of women's health and fertility IP rarely get more), add the net cash or subtract the net debt, and compare to where COO trades as a blended multiple. Today's ~14x blended EV/EBITDA implicitly values CSI too cheaply or CVI in line — meaning the stock compounds if CVI keeps growing 5-7% organically and CSI margins just normalize back to FY23 levels.

What to watch, ranked: (1) CVI organic growth and the single-use mix shift — these are the value creators; (2) MiSight uptake especially in Japan where MHLW approval just landed and the myopia population is 40%+ of school-age children; (3) CSI segment operating margin recovering from 3% — this is optionality, not the base case; (4) interest expense trajectory as the 2021 Term Loan refinances before December 2026; (5) FX — roughly half of sales are ex-US, so a strong dollar clips 3-5% off reported growth.

What the market may be missing. The bears' LASIK/GLP-1/digital-vision narrative has been around for twenty years and the installed base of soft contact lens wearers has grown through all of it. The more credible bear case is not demand destruction but competitive displacement — J&J and Alcon both launched premium dailies in 2023-24 with claims of better comfort metrics, and if Cooper's MyDay premium lineup doesn't refresh fast enough, unit share can leak even as the category grows.

What would change the thesis. CVI organic growth under 3% for a full year. A Paragard-style blockbuster issue on any of the IVF/cryostorage product lines (litigation, recall). A material impairment on Cook Medical goodwill within three years of the deal closing. The dividend was cut in December 2023 to redirect cash to buybacks — a reversal (restoring the dividend under pressure) would signal management has run out of M&A opportunities that beat buybacks, which is actually the moment the stock gets more interesting, not less.

The Numbers

Cooper is two high-quality franchises — contact lenses (CooperVision) and fertility/women's health (CooperSurgical) — priced like a slowing medtech but still running a premium sticker (P/E 37, EV/EBITDA 15). The numbers confirm a durable gross-margin business with Quality Score 90 and a 20-year revenue CAGR around 13%, but they also show the bill from a decade of levered M&A: ROIC has compressed to about 3.8%, GAAP EPS has gone sideways since FY2019, and FCF/NI conversion has been lumpy (0.7x–1.2x) because capex and acquisition spend keep eating the cash. The single variable most likely to rerate this stock is organic growth at CooperVision reaccelerating back to 7%+ — or, alternatively, JANA Partners' activist push forcing a breakup/merger with Bausch+Lomb that crystallizes the sum-of-the-parts gap.

A. Snapshot

Price ($)

$64.96

Market Cap ($M)

$12,992

Quality Score (0–100)

Fair Value ($)

$102.70

Revenue TTM ($M)

$4,152

Quality Score is a 0–100 composite of profitability, growth, financial health, and momentum sub-ranks. Fair Value is a model estimate anchored on historical multiples, earnings power, and sector benchmarks.

The stock has given back roughly a third from its 52-week high near $90. A Quality Score of 90 and a Fair Value estimate near $103 imply the market is pricing a durable growth slowdown, not a balance-sheet problem.

B. Quality scorecard — is this a well-run business?

No Results

Two-sentence read. The scorecard is a classic "great business, priced in" signature: Cooper posts top-decile profitability and growth sub-ranks, a comfortable Altman Z of 3.4, and no earnings-manipulation signal on the Beneish M-score. The only soft spot is the balance-sheet sub-rank of 6 — a legacy of Cooper's $2.5B net-debt load from a decade of acquisitions.

C. Revenue and earnings power — 20-year view

Revenue roughly 5x'd from 2006 to 2025 (~9% CAGR) with two visible step-ups — the CooperSurgical expansion through FY2018 and the Cook Medical acquisition in FY2022. Operating margin has held a wide 13–22% band with distortions from amortization of acquired intangibles; FY2021's net margin spike is a one-off tax benefit. The trend most worth knowing: FY2025 operating income dipped about 3% YoY even as revenue grew 5%, signaling operating leverage has flattened.

Recent quarterly trajectory

Organic growth has decelerated from double-digits in FY2023 into the mid-single-digits through FY2025 — the exact slowdown activist Jana Partners flagged when pushing management to re-examine the portfolio. 1Q FY26 nudged back to 6.2%, with CooperVision up about 4% and CooperSurgical up about 6%.

D. Cash generation — are the earnings real?

Operating cash flow has run consistently above GAAP net income (FY2021's net-income spike was a one-off tax benefit; ignore the optical mismatch). The meaningful issue is capex intensity — annual capex climbed from roughly $150M in FY2016 to about $400M through FY2023–24 as Cooper built out lens capacity. FCF/NI has averaged about 1.1x over five years but swung from 0.7x to 1.2x; FY2023's 0.55x FCF/revenue was the tightest period and coincided with the stock's de-rating.

E. Capital allocation — where did the cash go?

Cooper has run a roll-up, not a return-of-capital story. Roughly $4.3B of acquisitions since FY2016 (Cook Medical at $1.6B in FY2022 the biggest swing) dwarfs about $653M of buybacks and only about $24M of dividends — the company eliminated its dividend in FY2024 to consolidate into a 4-for-1 split and opportunistic repurchase. FY2025 marked a visible pivot: $290M of buybacks versus only $11M of M&A, the first year in a decade dominated by return of capital.

F. Balance-sheet health

Net debt sits at about $2.4B against $1.04B of EBITDA — 2.3x, down from a 3x peak after the Cook Medical deal but still the highest leverage inside its peer group. Altman Z of 3.44 and interest coverage of 6.8x both signal safe, not fragile, but leverage is the reason the balance-sheet sub-rank is only 6/10 and the reason dividends remain off the table.

G. Valuation — 20-year self vs today

Current P/E

37.4

▲ 34.2 vs 20y mean

Current EV/EBITDA

15.4

▲ 17.9 vs 20y mean

Fair Value Gap

58.0%

This is the critical chart. On P/E Cooper sits roughly in-line with its 20-year and 5-year means (37x), so the stock is not "screening cheap" by headline earnings. The more informative read is EV/EBITDA at 15.4x — roughly 0.4 standard deviations below the 20-year mean of 17.9x and a full 5 turns below the 5-year mean of 20.5x. That is the first time EV/EBITDA has traded under the 20-year average since the 2008–10 GFC window. The disconnect: the market has compressed EBITDA-based valuation while P/E stays elevated because amortization and interest are growing with the debt stack.

H. Peer comparison

No Results

Cooper screens cheap only against Alcon and Edwards on EV/EBITDA (15x vs 31x), and it is more diversified than either. The gap to watch is ROIC — Cooper's 3.8% is less than a quarter of what Hologic (15%) and Edwards (20%) earn on capital, because Cooper has put almost $4B into goodwill over the last decade. That is the precise frustration behind the Jana Partners activist campaign: the portfolio is worth more than the sum of its returns.

I. Fair value and scenario

No Results

Consensus 12-month analyst target sits around $85 (range $65 Goldman Sachs sell to $100+ at Needham/JP Morgan), and the model Fair Value is $103 for a ~58% upside gap. The bull case does not require operational heroics — it requires the activist-push sum-of-the-parts to be recognized. The bear is that lens market share erosion versus Alcon continues and growth stays in the 3–4% band that typically earns an 11–12x EV/EBITDA.

What to watch

The numbers confirm Cooper is a high-quality duopoly-adjacent medtech: 65% gross margin, 90 Quality Score, Altman Z of 3.4, predictable 4.5-star earnings. The numbers contradict the "contact-lens compounder" narrative — GAAP EPS is flat since FY2019 and ROIC is below WACC at about 3.8% because a decade of acquisitions loaded $3.8B of goodwill onto the books. What to watch next is CooperVision organic growth reaccelerating above 6% (the threshold where it historically earned a premium multiple) and any board response to JANA Partners' ongoing push for portfolio action — either one would reset the EV/EBITDA ceiling.

The People

Grade: B. Governance here is clean on paper — fully independent board, no related-party transactions, strong clawback, meaningful ownership guidelines — but the tape shows a company under pressure: TSR has lagged the healthcare-equipment peer group by ~37 points over four years, activist investor Jana Partners is pushing to break up CooperVision and CooperSurgical, and Browning West has already placed a director (Walter Rosebrough) through a December 2025 cooperation agreement. The offset, and it is a real one, is that ten insiders — including the CEO twice — bought $2.52 million of stock on the open market in 2025 with zero sales. That is a rare, unambiguous signal of internal alignment even as outside capital is demanding structural change.

The People Running This Company

No Results

Albert G. White III — CEO. Joined Cooper in 2006 from KeyBanc Capital Markets, climbed through Investor Relations, Treasurer, Chief Strategy Officer, and CFO before taking the CEO job in 2018. He ran CooperSurgical as an EVP before becoming CEO — which is exactly the fact Jana Partners weaponized in its October 2025 campaign: the company's leader has never run the contact lens business that generates two-thirds of revenue. White has never held a line role at a vision peer. He does sit on Evolus (EOLS) as Compensation Committee Chair.

Brian G. Andrews — CFO. Insider hire, has been Treasurer since 2013 and CFO since 2018. Columbia econ, ex-KeyBanc like White. No prior public-company CFO experience before Cooper, but ~20-year tenure.

Daniel G. McBride — COO/GC. Lawyer (Stanford Law, Latham & Watkins M&A practice) who has been COO since 2013 and took the General Counsel title back in October 2025 in what looks like a consolidation move. Largest shareholder on the executive team after White (685,784 beneficial shares, mostly via options).

Holly R. Sheffield — President, CooperSurgical. Ex-UBS Global Head of Medical Tech (2009–2018). Banker in the line role — she architected many of the CooperSurgical deals, then was promoted to run the division. Strong dealmaker resume; operating track record is what Jana is questioning.

Gerard H. Warner III — President, CooperVision. The only NEO with deep contact-lens operating history: 17 years at Bausch + Lomb before joining CooperVision in 2012. Runs the crown-jewel segment.

Succession depth is thin. White, Andrews, and McBride have spent most of their careers inside Cooper; Warner is the only operator with meaningful outside industry experience. If Jana succeeds and the company is split or if White exits, Cooper does not have an obvious internal CEO-for-contact-lenses beyond Warner.

What They Get Paid

No Results

Does the pay work? Total CEO compensation of $16.05M sits inside the peer group (Agilent, Illumina, Align, DexCom, Edwards, Zimmer Biomet, etc., $1.8B–$7.4B revenue). The structure is textbook best-practice: 93% of White's target comp is performance-linked, 85% of the annual cash bonus depends on quantitative financial metrics (revenue, non-GAAP EPS, free cash flow), and PSUs have a three-year cliff tied to constant-currency EPS CAGR. Say-on-Pay passed with ~90% support at the 2024 meeting.

Where the math gets interesting is "Compensation Actually Paid." White's CAP collapsed from $39.8M in FY24 to $1.77M in FY25 — a 96% drop — because the stock price fell and his unvested equity is marked to market. That is the plan working: when TSR drops from $100 to $67 over four years, the realized pay drops with it. FY22 CAP was actually negative.

The CEO pay ratio is 331:1 ($16.05M vs. $48,540 median employee). That is above peer group medians but not unusual for a globally distributed medical device company with low-cost manufacturing.

Starting FY2026, the OCC is adding relative TSR vs. the S&P Healthcare Equipment Index as a 25% PSU weight — a direct response to the last four years of peer underperformance and exactly what a proxy advisor would ask for.

Are They Aligned?

Ownership and Control

No Results

No founder, no dual-class, no controlling shareholder. Index funds dominate the register — Vanguard (11.6%), BlackRock (7.1%), Capital World (5.5%). All 13 directors and officers together own 2.08%. The CEO owns 1% outright. This is a pure institutional-owned US large-cap. The control lever is proxy voting — exactly the lever Jana is now testing.

Insider Buying vs Selling — The Strongest Signal on the Page

No Results

**Ten open-market purchases, zero sales in 2025.** Every single NEO (White, Andrews, McBride, Sheffield, Warner) bought stock with personal cash after the Q3 guidance-cut sell-off on Sept 5. Four independent directors joined in. CEO White put in $1.49 million across two transactions. This is the cleanest insider signal you can read on a public company.

The September buys came right after the stock fell 12.85% on the Q3 earnings call when Cooper cut full-year guidance. The December buys came after Jana Partners announced its activist position. Two things both true: management is not selling into the controversy, and they are spending real personal cash at prices that are still well below the 52-week high.

Dilution and Capital Return

In FY2025, Cooper repurchased $290.1M (4.1M shares) at an average of $69.30 — into the teeth of the sell-off. The Board expanded authorization to $2 billion in September 2025. Q1 FY26 saw another $92.5M at $82.04. Management is using cash to shrink the float even while funding the balance-sheet work (debt reduction, restructuring charges of ~$89M taken to deliver ~$50M of annual run-rate savings). This is disciplined capital allocation, not empire-building — it is a meaningful behavior change from the 2017–2024 stretch Jana criticized as "siphoning cash into CooperSurgical."

The 2026 proxy is explicit: zero related-party transactions requiring disclosure during fiscal 2025. The policy is tight (Audit Committee pre-approval, KPMG audit review, clear carve-outs only for ordinary-course items). No pledging, no hedging, prohibited by policy. No stockholder rights plan ("poison pill"). Proxy access is standard.

Skin-in-the-Game Score

Skin in the Game (1–10)

7 / 10. The CEO owns roughly $126M of stock at the recent $65 price (1.94M shares at 1% of the company), well above the 6× salary guideline ($7.1M) that the OCC just increased from 5×. All NEOs comply. Insider purchases in 2025 were decisive and collectively priced-in the downside. The score is not higher because (a) directors' individual holdings are small — several hold well under $1M — and (b) a large portion of "ownership" is in exercisable but in-the-money options rather than paid-for shares.

Board Quality

No Results

Directors

Independent

Female Directors

Avg Age

Strengths. Eight of nine directors are independent (all except CEO White). The Chair (Colleen Jay) is independent. Five of nine are women. All three standing committees are fully independent. Audit Committee chair (Teresa Madden) is a Fortune-300 retired CFO with an active CPA license; her committee includes a retired KPMG Audit Partner (Carbone). Compensation Committee is chaired by an ex-P&G Global Division President and includes an ex-public-company CEO (Kurzius) who doubled his company's market cap. The Browning West-placed director (Rosebrough, joined January 2026) is the real ringer: during his 14-year CEO tenure at STERIS, shareholders compounded at 18% annually versus 10% for the S&P 500, and he has explicit medical-device M&A and operational transformation experience.

Weaknesses. Two structural issues. First, Bob Weiss has been on the Board since 1996 and was CEO until 2018; classifying him as "independent" is technically correct under Nasdaq rules (he has been off the payroll more than three years) but functionally he is not an outsider — he hired White and built the current strategy. Second, no director attended the 2025 annual meeting of stockholders, which is a minor but telling signal on shareholder engagement. The "directors may not serve on more than three other public boards" rule is well-followed; the busiest director has two outside boards.

**Activist pressure has already reshaped the board.** Carbone (2025), Rosebrough (2026) are both recent additions, and Rosebrough's seat came through an explicit December 2025 letter agreement with Browning West, LP. The board is visibly responding. Expect Jana's campaign to put further pressure on composition and committee chairmanships.

The Verdict

Skin in the Game

Independent Directors (of 9)

Grade: B.

Strongest positives. (1) Ten open-market insider buys in 2025 with zero sales, led by the CEO putting $1.49M of personal cash to work across two separate tranches — the sell-side's favorite insider signal. (2) Clean governance mechanics: independent Chair, fully independent committees, no related-party transactions, no poison pill, no dual-class, robust clawback, hedging/pledging prohibited, ownership guidelines just raised from 5× to 6× salary for the CEO. (3) Disciplined capital return — $383M repurchased in FY25 + Q1 FY26 at declining prices. (4) Real pay-for-performance — CEO CAP fell 96% in FY25 as TSR lagged peers, and FY26 equity will include a relative-TSR PSU component.

The real concerns. (1) Strategy credibility. Jana Partners' critique is economically serious: Cooper has deployed $3B into CooperSurgical since 2017, returns on capital have declined, and the CEO was the former head of CooperSurgical. The board signed off on every piece of that plan. (2) TSR underperformance. Cumulative TSR of $67 vs. peer group $104 over four years is not a rounding error — it is the reason activists are here. (3) Board refresh is reactive, not proactive. Rosebrough is a strong add, but he is there because Browning West demanded a seat. Left alone, the board added one director (Carbone) in four years.

Upgrade catalyst: public, specific, time-bound engagement on portfolio separation or on CooperSurgical ROIC improvement — i.e., the board moves from passive acceptance of Jana's thesis to driving the strategic review itself. Any of: formal strategic review announcement, sale of a non-core CooperSurgical asset, or a clean contact-lens operator added to the Board.

Downgrade catalyst: management publicly dismisses Jana's campaign, insider buying pattern reverses in 2026, or any governance erosion (renegotiated CEO package, added perquisites, or a poison pill in response to activism).

The Full Story

For five years the story was the same: Cooper is a two-pillar medical-device compounder — contact lenses (CVI) and women's health/fertility (CSI) — levering up to buy growth and riding a post-COVID rebound to double-digit organic growth. That narrative survived through fiscal 2024, then quietly changed in 2025. Organic growth stepped down from 8% to 4%, management stopped celebrating "double-digit" and started celebrating "eight consecutive earnings beats," CSI fertility decelerated sharply, and the company executed a $89M reorganization that was never pre-announced and yielded only a $50M/yr save. Credibility on EPS remained strong throughout; credibility on revenue has softened.

**What changed.** Growth algorithm reset from "high-single/low-double organic" (2022-24) to "mid-single organic" (2025-26). **What did not change.** Two-segment structure, Al White as CEO since 2018, MyDay/MiSight as the growth engine, willingness to lever up for M&A. **Credibility direction.** EPS delivery improved; revenue pattern deteriorated and guidance ranges were walked down three times in fiscal 2025.

1. The Narrative Arc

No Results

The interesting inflection is fiscal 2025, not fiscal 2022. The Generate + Cook acquisitions in 2022 were continuity — Cooper has been a serial acquirer for decades. What broke the pattern was fiscal 2025, when the M&A story stopped being the answer to every question and the story became about cost structure, cash generation, and share count.

2. What Management Emphasized — and Then Stopped Emphasizing

Heatmap

Catalog Error: Table with name themes does not exist!
Did you mean "pg_tables"?

LINE 2: ...'FY2022' as fy, 2022 as yr_sort, theme, fy22 as intensity from themes union all
                                                                          ^

What got louder. Free cash flow moved from a routine reconciliation line in fiscal 2022 to the headline metric by fiscal 2026. Cooper never issued explicit annual FCF guidance before FY2026 — the initial FY26 guide of $575-625M plus a three-year $2.2B FCF commitment is a new contract with investors. Share repurchases, dormant from 2017 through 2024 (only ~$78M in FY22, zero in FY23-FY24), jumped to $290M in FY25 and the authorization was tripled to $2B in September 2025.

What got quieter. "Nine consecutive quarters of double-digit organic revenue growth" (Q2 FY23) and "tenth consecutive quarter of double-digit fertility growth" (Q2 FY23) were signature talking points for two years. By FY2025 they had disappeared from the script. Fertility grew 1% in Q4 FY25 and 3% in Q1 FY26 — the streak broke and management never acknowledged it. The Cook Medical acquisition, which cost a $45M termination accrual in 2Q23, was eventually completed (referenced as acquired in FY24 reconciliations) but was never celebrated as the strategic prize it was originally framed as.

3. Risk Evolution

The most visible pivot is tariffs. In FY2021-FY2024 tariffs were a single bullet inside the boilerplate international-operations risk. In fiscal 2025 tariffs became a standalone risk factor with its own heading — "Economic and trade sanctions, including tariff and import/export regulations… could make it more difficult or costly" — and in Q1 FY26 Cooper explicitly called out that gross margin would have been flat "excluding the impact of tariffs." This is not foreshadowing; this is a live P&L issue.

Newly visible: inflation gets its own heading for the first time in FY2022 and persists. Quietly dropped: Brexit (material in FY21, gone by FY23); COVID-19 (dominant in FY21-22, gone by FY24). Escalating steadily: cybersecurity, EU MDR/IVDR compliance, customer consolidation — the last is especially relevant as the consolidation of optical retail chains and fertility clinic networks changes the bargaining structure of both businesses.

4. How They Handled Bad News

Cooper's bad-news handling style is consistent: soften it with a forward bridge, never dwell on the cause, and raise something else to distract. Two episodes stand out.

Episode 1 — Cook Medical termination (Q2 FY2023)

Cooper accrued $45M in Q2 FY2023 for "probable payment of a termination fee" on the Cook Medical Reproductive Health deal originally signed February 2022. Rather than explain what went wrong, the press release buried the accrual in footnote B of the reconciliation table and pivoted the CEO quote to the "ninth consecutive quarter of double-digit" CVI growth. The deal ultimately did close (it reappears as an acquired business in FY2024 reconciliations), meaning Cooper paid a termination fee and completed the acquisition — a fact never spelled out in plain language in any press release we can find. The SightGlass Vision joint-venture deconsolidation a quarter earlier (FY22) followed the same pattern: framed as a $56.9M gain, not as a walk-back from a standalone myopia-spectacle strategy.

Episode 2 — The FY2025 organic growth reset

FY2025 guidance was initiated at 6-8% organic revenue growth in Q4 FY2024, walked down to 5-6% after Q2 FY25, then to 4-4.5% after Q3 FY25. Actual FY25 organic growth was 4%. The explanation evolved in lockstep without acknowledging the pattern:

The pattern is consistent: revenue misses are absorbed quietly, EPS is protected through expense leverage and reorganization, and the forward narrative moves on. No CEO or CFO change followed. No acquisition was blamed by name.

5. Guidance Track Record

No Results

Three findings.

EPS delivery is reliable. FY23 landed at the initial midpoint ($12.81 non-GAAP EPS, pre-split). FY24 beat by 7% on a post-split basis ($3.69 actual vs $3.45 initial midpoint). FY25 beat by 4% despite the revenue miss ($4.13 vs $3.97 initial). Cooper has now delivered eight consecutive quarters of non-GAAP EPS beats — a claim management made explicitly in the Q4 FY25 release.
Revenue delivery has degraded. FY23 beat the initial guide by 1.5%. FY24 beat by 1.3%. FY25 missed the initial midpoint by 0.7% — a small miss in absolute terms but a large miss against organic growth expectations (guided 6-8%, delivered 4%). FY25 is the first revenue miss in the observable window and it came without prior warning — initial guide was held through Q1 FY25 and only started coming down in Q2 FY25.
The walk-down pattern matters. Management's language in Q2 and Q3 FY25 emphasized raising EPS guidance while revenue was being trimmed — a useful distraction that worked against consensus but not against the initial annual guide. This is the first fiscal year in the observable window where guidance was revised down on a measure that matters.

Credibility Score (1-10)

Credibility score: 7/10, trending down from 8. EPS delivery, cash flow, and share-repurchase execution are strong. Revenue guidance is no longer dependable as a single-point estimate — ranges have widened, mid-year revisions are larger, and the gap between "double-digit organic" talk and mid-single-digit delivery has opened up. Management has not explicitly reset long-term revenue expectations; until they do, investors should treat annual revenue guides as aspirational and EPS guides as closer to commitments.

6. What the Story Is Now

Cooper in 2026 is no longer a "high-single to low-double-digit organic compounder levering up for tuck-ins." It is a mid-single-digit organic grower with a cash-return pivot underway. The FY26 guide of 4.5-5.5% organic revenue, $4.58-$4.66 non-GAAP EPS, and $600-625M free cash flow — backed by a three-year $2.2B FCF objective and a $2B repurchase authorization — is a materially different investor contract than the one that existed through fiscal 2024.

De-risked:

EPS delivery mechanics (eight straight beats)
Debt trajectory (long-term debt down ~$600M year-over-year post Q1 FY26; refinanced to short-term)
MiSight myopia franchise (FDA, China NMPA, Japan MHLW approvals now in hand; Q4 FY25 up 37%)
Capital-return credibility (share count down ~5M in FY25, first meaningful buyback since 2017)

Still stretched:

CSI fertility growth (was 10+% for a decade, printed 1-3% in recent quarters; management calls FY26 "a much stronger year" with no specific catalyst named)
Tariff pass-through (already a headwind to Q1 FY26 gross margin; exposure to Costa Rica, Hungary, UK manufacturing is geographically concentrated)
The $50M/yr reorganization save on a $89M one-time charge (17-month payback is fine; but the reorg was reactive, not pre-announced, raising the question of what else is being quietly restructured)
Revenue guidance credibility (one miss is an event; two would be a pattern)

Believe vs discount. Believe the cash-generation commitment — the FCF guide is new, specific, and tied to explicit debt paydown and repurchase actions that can be checked every quarter. Discount the "double-digit growth is back" framing if it returns in any CEO quote in FY26 — the five-year evidence says Cooper's underlying growth rate has stepped down to mid-single digits, and the FY26 guide of 4.5-5.5% organic implicitly confirms that. The reset is real; the question is whether management is ready to say so in plain language.

What's Next

The next 3 to 6 months are dominated by one overlapping question: does the activist clock (JANA plus Browning West) force portfolio action before management's own capital-return contract (three-year $2.2B FCF, $2B buyback) earns the re-rate on its own. Two earnings prints, the first Rosebrough-era board meetings, and the December 2026 term-loan maturity are the observable markers.

Latest reported (Q1 FY26): EPS $1.10 vs consensus $1.03 (+6.8% surprise). COO has beaten in each of the last nine quarters, so the bar is less about the print and more about the guide. The specific things the market will watch most closely:

CooperVision organic growth rate — bull's disconfirming signal is two consecutive quarters below 3%; bear's confirming signal is a second walk-down of the 4.5-5.5% FY26 guide.
Fertility print — CooperSurgical fertility was 1% in Q4 FY25 and 3% in Q1 FY26; whether it returns toward high-single digits will decide if the "Trump IVF overhang" reading was real or a structural reset.
Any board statement on strategic review — JANA's CVI-to-Bausch+Lomb proposal and Browning West's CSI-sale alternative both need a board response; silence through Q3 FY26 tips the clock toward 2027 proxy pressure.
Tariff / gross-margin commentary — Q1 FY26 disclosed tariffs kept gross margin flat; any escalation hits 65.5% GM directly.

For / Against / My View

For

Bull's price target: $103 per share, 12-18 months — anchored on model Fair Value of $103 (Numbers tab), which implies ~18x EV/EBITDA (the 20-year mean) on ~$1.1B EBITDA. No multiple expansion beyond reversion to long-run average, no growth heroics. Bull-case upside to $115-$150 if a JANA-driven breakup or CVI-only multiple recognition occurs.

First sub-20-year-mean EV/EBITDA since 2010

COO trades at 15.4x EV/EBITDA, roughly 0.4 standard deviations below the 20-year mean of 17.9x and a full 5 turns below the 5-year mean of 20.5x — the first time the stock has been below its long-run average since 2008-2010. Model Fair Value is $103 versus a $64.96 close, a 58% gap, with Quality Score at 90/100 and Altman Z at 3.44 (safe).

Evidence: Numbers — "EV/EBITDA at 15.4x — roughly 0.4 standard deviations below the 20-year mean of 17.9x and a full 5 turns below the 5-year mean of 20.5x. That is the first time EV/EBITDA has traded under the 20-year average since the 2008-10 GFC window"; Fair Value $103 vs price $64.96 = 58% gap; Quality Score 90/100; Altman Z 3.44.

Every NEO bought stock with personal cash; zero sold

Ten open-market insider purchases in 2025, zero sales. CEO Albert White put in $1.49M of personal cash across two tranches (10,000 shares at $68.39 in September, another 10,000 at $80.80 in December). The CFO, COO/GC, President of CooperVision, and President of CooperSurgical all bought. Four independent directors joined. CEO "Compensation Actually Paid" collapsed 96% from $39.8M to $1.77M as TSR lagged — the pay plan is penalizing management, and they are still buying.

Evidence: People — "Ten open-market purchases, zero sales in 2025. Every single NEO (White, Andrews, McBride, Sheffield, Warner) bought stock with personal cash… CEO White put in $1.49 million across two transactions"; CEO CAP fell from $39.8M (FY24) to $1.77M (FY25) — a 96% drop as TSR moved from 100 to 67.

Activist catalyst is already live and structurally mispriced

JANA Partners is publicly pushing to break up CooperVision and CooperSurgical; Browning West has already placed director Walter Rosebrough (ex-STERIS CEO, 18% annualized TSR over 14 years) through a December 2025 cooperation agreement. Sum-of-parts math is compelling: CVI alone on Alcon's 18-22x EV/EBITDA multiple plus CSI on 11-14x against a blended 14x today implies a re-rating without any operational heroics. The board has already refreshed itself reactively — the next escalation is a strategic review or asset sale.

Evidence: People — "activist investor Jana Partners is pushing to break up CooperVision and CooperSurgical, and Browning West has already placed a director (Walter Rosebrough) through a December 2025 cooperation agreement"; Business — "Do a sum-of-parts: put CVI on 18-22x EV/EBITDA (its peers Alcon and J&J Vision Care trade there), put CSI on 11-14x"; Numbers bull case — "$115-$150 — Jana-driven breakup or re-rating to 22x EV/EBITDA."

Against

Bear's downside target: $54 per share, 12-18 months — methodology: apply 12x EV/EBITDA (midway between GFC-era trough of 8x and current 15.4x) to flat FY26 EBITDA of ~$1.04B = EV $12.5B, less ~$2.4B net debt = equity ~$10.1B on 198M diluted shares. Primary trigger: a second consecutive year of initial revenue guide being walked down by Q2 or Q3 FY26.

The growth algorithm already reset — and management still will not say so

FY25 initial organic revenue guide was 6 to 8 percent; actual was 4 percent, after three sequential walk-downs (6 to 8, then 5 to 6, then 4 to 4.5). CooperSurgical fertility — branded with "ten consecutive double-digit quarters" through FY23 — printed 1 percent in Q4 FY25 and 3 percent in Q1 FY26, and the streak was never acknowledged on a call. The FY26 initial guide of 4.5 to 5.5 percent organic implicitly confirms the new run rate, yet the stock still carries a FY25 P/E of 37 and a 5-year average EV/EBITDA of 20.5x — multiples earned when the business was compounding at double digits. A mid-single-digit medtech does not get 37x earnings once the buyside has watched the miss-and-reset pattern run twice.

Evidence: Story — "FY2025 guidance was initiated at 6-8%… walked down to 5-6%… then to 4-4.5%. Actual FY25 organic growth was 4%" and "Fertility grew 1% in Q4 FY25 and 3% in Q1 FY26 — the streak broke and management never acknowledged it." Numbers — 1Q25 yoy 3.6%, 4Q25 yoy 4.6% per quarterly_rev_yoy; current P/E 37.4 vs 20y mean 34.2 (val_anchors).

Sub-WACC ROIC exposes a decade of roll-up destruction

Reported ROIC of 3.8 percent is less than a quarter of Hologic's 15 percent or Edwards' 20 percent — because Cooper has put roughly $4.3 billion of acquisitions onto the books since FY16 (Cook Medical $1.6B in FY22; Generate Life $1.6B; obp Surgical $343M in FY24), carrying about $3.8B of goodwill. GAAP EPS is flat from FY19 to FY25; net income of $375M in FY25 is below $467M in FY19 despite revenue growing 54 percent over that span; and CooperSurgical operating margin collapsed from 9 to 3 percent on the Cook and obp integrations. The capital-return "pivot" is a tacit admission the deal pipeline does not clear the hurdle rate.

Evidence: Numbers — "ROIC has compressed to about 3.8%"; "about $4.3B of acquisitions since FY2016"; "CSI's operating margin collapsed from 9% to 3% in FY25" (Business). GAAP net income: 2019 $467M vs 2025 $375M (revenue_earnings_20y). People — Jana's October 2025 campaign on "$3B into CooperSurgical since 2017, returns on capital have declined, and the CEO was the former head of CooperSurgical."

The tape is methodical distribution, not a panic bottom

COO closed at $64.96 on April 23, 2026 — down 44 percent from the 2024 high of $115.90, 11th percentile of 52-week range, below the declining 200-day, RSI 26 with no bullish divergence, MACD back below zero after a failed lift. The last three earnings prints each produced a volatility spike (30-day realized vol hit 48 to 53 percent in April, June and September 2025) — serial repricing on each fundamental data point, not a single-shock drawdown. Relative strength has lagged SPY by 104 points and XLV by 42 points over three years and the gap is widening. Insider buying at $65 to $84 (September and December 2025) is already underwater.

Evidence: Technicals — "down roughly 44% from its 2024 all-time high," "11 points out of 100 on its own 52-week range," "RSI at 26," "Lagged SPY by 104 points and XLV by 42 points over 3 years," "Lose $61.78… the next visible support is the 2022 low near $63." People — CEO bought 10,000 shares at $68.39 on Sept 5 and 10,000 at $80.80 on Dec 16 — both above current $64.96.

The Tensions

1. Is 15.4x EV/EBITDA cheap, or correctly re-rated?

Bull says 15.4x is the first sub-20-year-mean print since the GFC and implies reversion to $103 with no growth heroics. Bear says the same 15.4x is still a premium for what is now a mid-single-digit grower with sub-WACC ROIC and a broken guide, and points out that the 20.5x five-year average was earned when organic was double-digit. Both cite the same data point: COO at 15.4x EV/EBITDA versus a 20-year mean of 17.9x and 5-year mean of 20.5x. This resolves on the FY26 initial guide credibility test at Q2 FY26 (late May 2026) and Q3 FY26 (August 2026) — two clean prints at 4.5 to 5.5 percent without a walk-down keeps the reversion case alive; one more walk-down confirms the bear's re-rating read.

2. Insider buying: conviction signal or anchor bias?

Bull says ten open-market buys with zero sales and $1.49M of CEO personal cash across two tranches is the cleanest alignment signal on a mid-cap. Bear says those exact same buys — 10,000 shares at $68.39 in September, 10,000 at $80.80 in December — are already underwater at $64.96, so the "most aggressive bull signal in the people tab is itself in the red." Both cite the same two CEO purchases at $68.39 and $80.80. This resolves on the next Form 4 window after Q2 FY26 earnings — a third open-market buy below $65 materially strengthens the conviction read; silence or a 10b5-1 sale schedule hardens the anchor-bias read.

3. The activist: catalyst or overhang?

Bull says JANA plus Browning West is the mechanism that crystallizes the sum-of-parts — CVI on 18-22x, CSI on 11-14x, blended 14x today. Bear says the activist campaign is precisely what a sub-WACC-ROIC conglomerate looks like when the market has stopped believing management, and absent an actual transaction it is an overhang that caps the multiple. Both cite the same JANA 13F position (3.5M shares, $289M, JANA's 2nd-largest holding) and the December 2025 Browning West cooperation agreement. This resolves on the Rosebrough Board Chair decision window (end of 2026) and any public board statement on strategic review — a formal review announcement or asset sale is the bull's proof; a 2027-proxy deferral with no transaction is the bear's proof.

My View

Close call, slight edge to the Against side for the next two quarters, and the reason is tension #1. The bull's "15.4x is cheap" argument and the bear's "15.4x is still a premium" argument sit on top of the same number, and the tie-breaker is whether the FY26 guide holds. Cooper has already walked down an initial guide three times in a single fiscal year; until we have seen Q2 FY26 and Q3 FY26 print inside the 4.5 to 5.5 percent band without a trim, the $2B buyback and the Fair Value anchor are catching a knife, not buying a trough. I would wait for the May earnings print before adding — the activist catalyst is real but it rhymes more with "overhang that eventually resolves" than with "imminent announcement," and Rosebrough's chair window is end of 2026, not next week. What would flip the view: one clean Q2 FY26 print with the 4.5 to 5.5 percent organic guide reiterated and CooperVision back above 5 percent — that turns the bull's mean-reversion math from hypothetical into probable, and the insider cash stops looking like an anchor.

Web Research

Bottom line from the web. Cooper is in the middle of a live, dual-front activist campaign that the 10-K and the proxy cannot fully capture: Jana Partners disclosed a $167M / 1.22%-of-company stake in late 2025 pushing to sell CooperVision to Bausch+Lomb, while Browning West (>$500M invested) is separately demanding the opposite trade — sell CooperSurgical and keep a pure-play vision company. The board has already settled with Browning West (Walt Rosebrough appointed Jan 3, 2026; likely Board Chair by end of 2026), Colleen Jay took over as Chair in January 2026, and Bausch+Lomb CEO Brent Saunders has publicly volunteered that a vision combination would "strengthen competition." The filings show a slowing compounder; the web shows a company whose corporate structure is explicitly in play.

What Matters Most

**#1 — Dual activist campaign with a director already seated.** Jana Partners bought 2,434,607 shares (Q3 2025, ~$166.9M, 8.08% of its portfolio) and is publicly pushing a CooperVision / Bausch+Lomb combination; Browning West holds >$500M and nominated four directors (Rosebrough, Joe Papa, Andy Pawson, Faraz Athar). On December 23, 2025 Cooper signed a cooperation agreement with Browning West, appointed Walt Rosebrough (18% annualized TSR as STERIS CEO 2007-2021) effective January 3, 2026, and committed to "due and serious consideration" of Rosebrough as Board Chair by year-end 2026 plus a second medtech-experienced director to be chosen with Browning West's consent. This is materially more concrete than "activist agitation" — Cooper has already ceded board composition rights. Sources: [globenewswire.com/CooperCompanies-Appoints-Walter-M-Rosebrough-Jr](https://www.globenewswire.com/news-release/2025/12/23/3209824/2200/en/CooperCompanies-Appoints-Walter-M-Rosebrough-Jr-to-its-Board-of-Directors.html), [cnbc.com/2025/11/15/jana-partners-push-to-break-up-cooper-cos](https://www.cnbc.com/2025/11/15/jana-partners-push-to-break-up-cooper-cos-could-change-the-stocks-outlook.html), [fiercebiotech.com/cooper-companies-under-activist-pressure-split-different-ways](https://www.fiercebiotech.com/medtech/cooper-companies-under-activist-pressure-split-different-ways).

**#2 — Bausch+Lomb's CEO is publicly inviting a deal.** Brent Saunders, a serial dealmaker, has stated on-record that combining with CooperVision would "strengthen competition and create a more scaled company in the contact lens segment." Jana's synergy estimate: $300-500M on $850M of CVI EBITDA. The combined global soft-lens share (~36%) would still sit just below market leader J&J (37%), which Jana's research argues minimizes antitrust risk. Source: [cnbc.com/2025/11/15](https://www.cnbc.com/2025/11/15/jana-partners-push-to-break-up-cooper-cos-could-change-the-stocks-outlook.html), [stocktwits.com/activist-investor-turns-up-heat](https://stocktwits.com/news-articles/markets/equity/activist-investor-turns-up-heat-on-cooper-urges-bausch-lomb-merger-to-boost-returns-report/ch6CWJvR3oK).

**#3 — The Cook Medical deal the filings allude to was terminated by FTC pressure, not closed.** The specialist writeups reference "Cook Medical integration costs" in CSI margins — but the original $875M Cook Medical reproductive-health acquisition (signed Feb 2022) was abandoned on August 1, 2023 after a full-phase FTC investigation concluded it would reduce competition in critical reproductive health markets. CooperSurgical later came back with a "doubled-back" slimmed-down deal, but the original thesis of a 2-year Cook subsidiary production transition was killed. This reframes the last three years of CSI ROIC drag: the capital was spent on the walk-away termination, integration redo, and smaller scope — not a completed acquisition that simply underperformed. Sources: [ftc.gov/statement-regarding-termination](https://www.ftc.gov/news-events/news/press-releases/2023/08/statement-regarding-termination-coopercompanies-attempted-acquisition-cook-medicals-reproductive), [massdevice.com/cooper-abandons-cook-medical-reproductive-acquisition](https://www.massdevice.com/cooper-abandons-cook-medical-reproductive-acquisition/), [fiercebiotech.com/after-ftc-scrutiny-coopersurgical-calls-875m-deal](https://www.fiercebiotech.com/medtech/after-ftc-scrutiny-coopersurgical-calls-875m-deal-cook-medicals-reproductive-health).

**#4 — MiSight Japan launched February 10, 2026, with 77% pediatric myopia prevalence as the addressable base.** CooperVision is now the only soft contact lens authorized in Japan for pediatric myopia control (US, China, Japan all approved). Up to 77% of Japanese elementary-school-aged children are myopic per MHLW/industry estimates — a much larger addressable pool than the ~40% figure used in most US modeling. Management called out MiSight +37% in Q4 FY25; the Japan launch adds a structurally different market. This is an under-appreciated growth option the market is treating as incremental. Source: [reachmd.com/coopervisions-misight-1-day-becomes-first-pediatric-myopia-control-contact-lens-available-in-japan](https://reachmd.com/news/coopervisions-misight-1-day-becomes-first-pediatric-myopia-control-contact-lens-available-in-japan/2485642/), [reviewofmm.com/misight-1-day-approval-in-japan](https://reviewofmm.com/misight-1-day-approval-in-japan/).

**#5 — Paragard's 40-year monopoly ended in February 2025.** The FDA approved Miudella (Sebela Women's Health), the first new hormone-free copper IUD since Paragard's original 1984 approval. Miudella uses less than half the copper, a 3.7mm flexible-nitinol insertion device, and a 3-year indication — directly addressing the "painful insertion" objection that drove some market share to hormonal alternatives. Sebela is planning broad US availability during 2026. Cooper disclosed a mid-teens decline in Paragard sales in Q2 FY25; the competitive runway just narrowed materially. Sources: [futurefemhealth.com/fda-approves-first-new-hormone-free](https://www.futurefemhealth.com/p/fda-approves-first-new-hormone-free), [medicine.iu.edu/2026-bernard-iud-clinical-trial-indiana](https://medicine.iu.edu/blogs/indiana-health/2026-bernard-iud-clinical-trial-indiana).

**#6 — Insider buying sits above $2.5M with zero sales; Rosebrough appointment was met with a 12% after-hours pop on Dec 3, 2025.** The ten open-market insider purchases in 2025 (led by CEO White putting $1.49M across two tranches) were not isolated — they preceded and followed both the Q3 FY25 guidance-cut sell-off and the Jana announcement. When the Q4 FY25 print on December 3, 2025 bundled a strategic review signal, a new Chair announcement (Colleen Jay), and an $89M reorganization charge translating to $50M in annual savings, the stock rose 12% after-hours. Message from the tape: the market is pricing the activist outcome as a positive, not a threat. Source: [gurufocus.com/cooper-cos-coo-surges-on-strategic-review-and-leadership-change](https://www.gurufocus.com/news/3234968/cooper-cos-coo-surges-on-strategic-review-and-leadership-chan).

**#7 — Q3 FY25 was the credibility break; Trump IVF-coverage comments the unexpected culprit.** Organic growth fell to 2% in Q3 FY25 from 7% the prior quarter; Cooper cut full-year guidance and the stock dropped 12.85% the next day. Jana's research attributed the fertility deceleration specifically to President Trump's public comments suggesting potential Federal reimbursement of IVF costs — prompting patients to delay cycles in anticipation of coverage. This is a political-risk narrative the specialists flagged but could not source externally; the web confirms it. Source: [cnbc.com/2025/11/15](https://www.cnbc.com/2025/11/15/jana-partners-push-to-break-up-cooper-cos-could-change-the-stocks-outlook.html).

**#8 — Goldman Sachs initiated with a Sell on October 1, 2025; JP Morgan cut PT to $66 (from $76) on August 28, 2025.** Sell-side sentiment is divided and skewing negative heading into the activist campaign. The current 17-analyst consensus target is $85.80 (range $64-$98). The Goldman Sell call (analyst David Roman, PT $64) puts a material downside anchor below the current price. Needham is the most bullish at the top end of the range (PT $94, raised June 17, 2025). Source: [gurufocus.com/goldman-sachs-initiates-coverage-on-cooper-companies-with-a-sell-rating](https://www.gurufocus.com/news/3127863/goldman-sachs-initiates-coverage-on-cooper-companies-coo-with), [defenseworld.net/cooper-companies-sets-new-52-week-low-on-analyst-downgrade](https://www.defenseworld.net/2025/08/29/cooper-companies-nasdaqcoo-sets-new-52-week-low-on-analyst-d).

**#9 — Tariffs are a live, disclosed gross-margin headwind into FY26.** Q4 FY25 non-GAAP gross margin was 66% (down 70 bps YoY) on tariffs and mix; Q2 FY25 disclosed ~$4M tariff cost of goods in-year, with management noting a "more complex global operating environment." Cooper manufactures through Costa Rica, Hungary, Puerto Rico, the UK, Belgium and the US — exactly the footprint exposed to US reciprocal tariffs (Section 232 ripple effects) and the 2025 "Liberation Day" tariff regime. KPMG's Q3 2025 executive survey: 32% of US companies reporting 1-5% gross margin decline, 22% reporting 6-10% — Cooper's disclosed impact is toward the lighter end, but the full-year FY26 rate depends on tariff regime persistence. Source: [ainvest.com/cooper-companies-slowing-growth-strategic-implications](https://www.ainvest.com/news/cooper-companies-slowing-growth-strategic-implications-long-term-2509/), [kpmg.com/tariff-business-impact-what-executives-think-now](https://kpmg.com/us/en/articles/2025/tariff-business-impact-what-executives-think-now.html).

**#10 — First-ever three-year free cash flow commitment: $2.2B+ FY26-FY28.** On the December 4, 2025 Q4 call, management issued the first explicit multi-year FCF guide in the company's history — over $2.2B of cumulative FCF from FY26 through FY28 — alongside the tripled $2B buyback authorization. This is the "new contract with investors" Jana's campaign helped force. In a breakup scenario, that FCF commitment becomes the floor for what the standalone pieces have to clear. Source: [insidermonkey.com/cooper-companies-q4-2025-earnings-call-transcript](https://www.insidermonkey.com/blog/the-cooper-companies-inc-nasdaqcoo-q4-2025-earnings-call-transcript-1655236/), [fool.com/earnings/call-transcripts/2026/03/05/cooper-coo-q1-2026-earnings-call-transcrip](https://www.fool.com/earnings/call-transcripts/2026/03/05/cooper-coo-q1-2026-earnings-call-transcrip).

Recent News Timeline

No Results

The Activist Structure — Two Plans, One Company

No Results

What the two plans have in common. Both agree Cooper's current structure is worth less than the sum of the parts. Both agree the CEO transition should bring a vision-native operator. Neither is asking for a dividend hike or a leverage cut. The disagreement is which segment goes — and that is a resolution question, not a thesis question. Both paths point to a break-up event within 12-24 months.

What the board has done. On December 23, 2025 Cooper signed a cooperation agreement with Browning West appointing Walt Rosebrough — a candidate Browning West had already nominated — to the board effective January 3, 2026, onto the Corporate Governance & Nominating Committee, with an explicit commitment to "provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board by the end of 2026" and to identify a second medtech-experienced director with Browning West's mutual agreement. Colleen Jay (P&G ex-Global Division President; director since 2016) became Board Chair in January 2026. Jana's plan has no such settlement yet; at the April 7, 2026 annual meeting all nine incumbent directors were re-elected and Say-on-Pay passed, so Jana's campaign is still in the "advisory" phase.

What the Specialists Asked

Analyst Landscape — Sell-Side is Split

No Results

Avg Target

$85.80

Low (Goldman)

$64

High (Needham)

$98

The split matters. Goldman's Sell at $64 is roughly current stock price — i.e., the bear seat is at the market, not below it. Needham's $94 prices roughly the Jana / activist resolution bull case with no operational heroics. The ~$34 range between bear and bull is unusually wide for a medtech large-cap and reflects the binary nature of the activist outcome: if a CVI breakup happens, $94+ is defensible; if management successfully rebuffs, Goldman's $64 is plausible.

Insider Spotlight — Conviction in the Face of Activism

No Results

Total 2025 insider open-market activity: 10 buys, 0 sells, $2,520,761 deployed. The pattern spans both sides of the Jana announcement — management bought before Jana was public and continued buying after. CEO White's two buys alone total $1.49M. All five NEOs (White, Andrews, McBride, Sheffield, Warner) participated, plus four independent directors. The tape did not find 10b5-1 plan disclosures for the White transactions specifically — timing and pricing are consistent with discretionary conviction buys rather than mechanical ones.

Jana Partners' ownership trajectory. Q3 2025 13F: 2,434,607 shares ($166.9M). Q4 2025 13F: 3,507,075 shares ($289M, +44% QoQ). COO is now Jana's 2nd-largest portfolio position at 15% of a $1.9B AUM. Jana is a net buyer of COO even as the position appreciates — a conviction signal consistent with the "push harder" activist playbook.

Industry Context

Contact lens category growth is decelerating to 4-6% in 2025, not 7-8%. The category-size estimates vary by research house ($11B Fortune Business Insights / $15.6B Research Nester / $20B GM Insights) but consensus CAGR has compressed from "high single digit" to "5-7%" globally. Silicone hydrogel / daily disposables remain the premium-mix driver (daily disposable segment projected 12.5% CAGR vs category 5-7%). North America still dominates at ~34-40% share. The relevant question isn't whether contact lenses are a good industry — they are — but whether the three leaders (J&J, Alcon, CooperVision) can keep taking price in a decelerating volume backdrop. CooperVision's FY25 organic gap vs category (-1-2 points) is real but not catastrophic.

IVF is structurally attractive but politically sensitive. $2B global market growing 4-6%, with aging-mother demographics providing a 15-year tailwind. Near-term: the Trump administration's public suggestion of Federal IVF coverage has created a "wait for potential reimbursement" air pocket in US demand. This is a pure timing headwind, not a demand destruction signal, and it will normalize once the policy question resolves either way.

Private equity is actively buying women's health platforms. Blackstone and TPG were reported as nearing a deal for Hologic (women's health diagnostics peer) — a data point that bolsters Jana's alternative plan of a private-equity-led CooperSurgical carve-out if management resists the CVI sale path. This is an active bidding environment, not a hypothetical one.

Tariffs are a top-of-mind margin headwind across med-tech. Per KPMG's Q3 2025 executive survey, 57% of US companies report 1-10% gross margin declines from the 2025 tariff regime. Cooper's Costa Rica / Hungary / UK / Belgium footprint is directly exposed but disclosed FY25 impact was only ~$4M COGS — at the lighter end of the industry distribution. FY26 impact will depend on reciprocal-tariff regime evolution.

Methodology note. This section synthesizes 42 Brave Search queries across 226 fetched pages (106 from phase-1 specialist-aligned research + 120 from phase-2 targeted specialist questions). Where claims contradict the filing-based specialist analysis, the contradiction is called out explicitly. Where the web is thin, the limit is called out. No speculation beyond what the sources state.